JP2006509751A5 - - Google Patents

Download PDF

Info

Publication number
JP2006509751A5
JP2006509751A5 JP2004554308A JP2004554308A JP2006509751A5 JP 2006509751 A5 JP2006509751 A5 JP 2006509751A5 JP 2004554308 A JP2004554308 A JP 2004554308A JP 2004554308 A JP2004554308 A JP 2004554308A JP 2006509751 A5 JP2006509751 A5 JP 2006509751A5
Authority
JP
Japan
Prior art keywords
component
composition
composition according
incontinence
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004554308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006509751A (ja
Filing date
Publication date
Priority claimed from EP02026546A external-priority patent/EP1424079A1/en
Application filed filed Critical
Publication of JP2006509751A publication Critical patent/JP2006509751A/ja
Publication of JP2006509751A5 publication Critical patent/JP2006509751A5/ja
Pending legal-status Critical Current

Links

JP2004554308A 2002-11-27 2003-11-03 β−３アドレナリン受容体アゴニストとセロトニン及び／又はノルエピネフリン再取り込み阻害剤とを含む医薬組成物 Pending JP2006509751A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026546A EP1424079A1 (en) 2002-11-27 2002-11-27 Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PCT/EP2003/012225 WO2004047830A2 (de) 2002-11-27 2003-11-03 Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen

Publications (2)

Publication Number Publication Date
JP2006509751A JP2006509751A (ja) 2006-03-23
JP2006509751A5 true JP2006509751A5 (enExample) 2006-12-21

Family

ID=32241298

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004554308A Pending JP2006509751A (ja) 2002-11-27 2003-11-03 β−３アドレナリン受容体アゴニストとセロトニン及び／又はノルエピネフリン再取り込み阻害剤とを含む医薬組成物
JP2004554318A Pending JP2006509752A (ja) 2002-11-27 2003-11-05 β−３アドレナリン受容体アゴニスト及び抗ムスカリン作用薬を含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004554318A Pending JP2006509752A (ja) 2002-11-27 2003-11-05 β−３アドレナリン受容体アゴニスト及び抗ムスカリン作用薬を含む医薬組成物

Country Status (22)

Country Link
US (2) US20050261328A1 (enExample)
EP (4) EP1424079A1 (enExample)
JP (2) JP2006509751A (enExample)
KR (1) KR20050088295A (enExample)
CN (1) CN1717230A (enExample)
AT (1) ATE399005T1 (enExample)
AU (2) AU2003285312A1 (enExample)
BR (1) BR0316535A (enExample)
CA (2) CA2507266A1 (enExample)
CO (1) CO5580754A2 (enExample)
DE (1) DE50310046D1 (enExample)
EA (1) EA009781B1 (enExample)
EC (1) ECSP055814A (enExample)
ES (1) ES2309371T3 (enExample)
HR (1) HRP20050467A2 (enExample)
MX (1) MXPA05005483A (enExample)
NO (1) NO20053088L (enExample)
PL (1) PL376259A1 (enExample)
RS (1) RS20050392A (enExample)
UA (1) UA81931C2 (enExample)
WO (2) WO2004047830A2 (enExample)
ZA (1) ZA200503282B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2005042021A2 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10356112A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用
EP1809591A1 (en) * 2004-10-26 2007-07-25 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
EP1852117A4 (en) * 2005-02-25 2010-10-27 Astellas Pharma Inc SOLIFENACIN CONTAINING PHARMACEUTICAL AGENT
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
US9440003B2 (en) * 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
US20100172988A1 (en) * 2006-01-10 2010-07-08 Kissei Pharmaceutical Co., Ltd. Sustained release preparation and method for production thereof
KR20090005237A (ko) * 2006-05-22 2009-01-12 테바 파마슈티컬 인더스트리즈 리미티드 둘록세틴 염산염 지연 방출형 제제
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
SI2216021T1 (sl) * 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
ES2376095B1 (es) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. Pellets entéricos de duloxetina.
WO2010053068A1 (ja) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
EP2316432A1 (de) * 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2377525A1 (en) * 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
PE20131341A1 (es) * 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
TW201338772A (zh) * 2012-02-09 2013-10-01 Altherx Inc 藥學組合物
SG11201502104YA (en) * 2012-09-18 2015-05-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CA3000230A1 (en) * 2015-10-15 2017-04-20 Duke University State-dependent peripheral neuromodulation to treat bladder dysfunction
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
EP3448366A1 (en) 2016-04-25 2019-03-06 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2017186593A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Tablets comprising mirabegron and solifenacin
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
CZ126598A3 (cs) * 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
WO1997025311A1 (en) * 1996-01-10 1997-07-17 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
PL328959A1 (en) * 1996-03-11 1999-03-01 Lilly Co Eli Method of treating or preventing interstitial cystitis
US6310103B1 (en) * 1996-07-19 2001-10-30 Bridge Pharma, Inc. S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
CA2263659A1 (en) * 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
WO1998021184A1 (en) * 1996-11-14 1998-05-22 Pfizer Inc. Process for substituted pyridines
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
JPH1112171A (ja) * 1997-06-19 1999-01-19 Nisshin Flour Milling Co Ltd 消化器疾患治療薬
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
KR100506568B1 (ko) * 1997-10-17 2006-04-21 아스텔라스세이야쿠 가부시키가이샤 아미드유도체및이의염,및이를포함하는약제학적제제
ATE250570T1 (de) * 1997-12-18 2003-10-15 Kissei Pharmaceutical Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
WO1999051564A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
ATE275126T1 (de) * 1998-04-14 2004-09-15 Kissei Pharmaceutical 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
DK1227806T3 (da) * 1999-11-11 2005-10-31 Pfizer Health Ab Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2001093683A1 (en) * 2000-06-07 2001-12-13 Watson Pharmaceuticals, Inc. Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
WO2002085871A2 (en) * 2001-04-04 2002-10-31 Wyeth Serotonergic agents with long-acting in vivo effects
WO2003035600A1 (en) * 2001-10-19 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Process for producing benzocycloheptene derivative
WO2003039464A2 (en) * 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence

Similar Documents

Publication Publication Date Title
JP2006509752A5 (enExample)
CO5580754A2 (es) Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina
JP5933176B2 (ja) タペンタドールの用量調節
US20090023744A1 (en) Combination therapy for depression
RU2675261C2 (ru) Фармацевтическая комбинация для лечения от боли
CA2716080C (en) Cns pharmaceutical compositions and methods of use
JP2013523775A (ja) 睡眠の質を改善するための方法
JPH083035A (ja) 医薬の応答反応の増強
JP2025508406A5 (enExample)
JP2007512273A5 (enExample)
TW201912153A (zh) 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
US20220062279A1 (en) Treatment of movement disorders
JP2007530620A5 (enExample)
JP2022506113A5 (enExample)
Sorbera et al. Dapoxetine hydrochloride
CN105848655B (zh) 用于注意力和认知障碍的、以及用于与神经变性障碍相关联的痴呆的新疗法
TWI409061B (zh) 莫達非尼於縮短抗抑鬱劑效果的開始時間的用途
JP2008509147A5 (enExample)
US20070123555A1 (en) Prevention and treatment of hearing disorders
US11207330B2 (en) Mirtazapine for use in medication overuse headache based on tension-type headache
JP2024534173A5 (enExample)
RU2004122639A (ru) Способ получения 1r,2s-метоксамина, его терапевтическое применение (варианты) и фармацевтическая композиция
JP2001508790A (ja) 治療薬を調製するためのβ▲下３▼−アドレナリン作動性受容体アゴニストの使用
CN116194092A (zh) 经口给予制剂
MX2013011079A (es) Composiciones farmaceuticas para el tratamiento del dolor agudo y neuropatico con base en el enantiomero activo (+)- tramadol o sus sales.